For the use with SOPHiA DDM™ to match tumor genomic profiles with targeted therapies
OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases, and SOPHiA GENETICS S.A., a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research, announced today an agreement facilitating the analysis and interpretation of genomic profiling.
Under the terms of the agreement, OncoDNA will customize OncoKDM® – OncoDNA’s interpretation platform – to make it compatible with SOPHiA GENETICS’ AI-powered SOPHiA DDM™ platform. The combined offering will enable the analysis and automatic translation of complex genomic data obtained via SOPHiA DDM™ into actionable recommendations, empowering customers to generate tumor genomic profiling insights and produce individual reports.
“We are proud to partner with SOPHiA GENETICS, a global leader in data-driven medicine, to improve access to molecular profiling and further facilitate the delivery of precision care to patients worldwide. By collaborating with them, we will be able to leverage our combined scientific and technical knowledge in oncology to provide an even more comprehensive solution that will enable laboratories to integrate large-panel genomic profiling into their workflows and outsmart the molecular complexity of cancer independently”, commented Jean-Pol Detiffe, Chief Strategy and Innovation Officer at OncoDNA.
“Combining OncoKDM® with our intuitive SOPHiA DDM™ platform, will further increase options for the interpretation of complex, high-volume genomic data to our global community and beyond,” added Lara Hashimoto, Chief Business Officer of SOPHiA GENETICS, “This partnership will allow us to continue to deliver on the promise and push the boundaries of precision medicine, ultimately benefiting even more patients worldwide.”
Prof. Alexandre Harlé, PU-PH at the Lorraine Institute of Oncology commented: “SOPHiA DDM™ platform is a powerful technology that has helped our laboratory to collect highly accurate insights into tumor cases. The addition of OncoKDM® will further advance our capabilities and help us keep track of the latest cancer treatment options. I am convinced that the combination of the technologies will bring an additional value to any lab. It will facilitate our routine work, enabling us to analyze an ever-growing panel of cancer-related genes rapidly, identify biomarker-associated drugs or clinical trials for more patients, and discuss complex cases through virtual meetings and tumor boards.”
OncoKDM® utilizes OncoDNA’s proprietary database, which is regularly updated with the latest drugs approved or in development. To date, it includes more than 4,500,000 genetic variants, 1,150 cancer drugs, and data from over 7,000 clinical trials.